17 results on '"Akremi R"'
Search Results
2. Burden Of Hospitalizations Related To Chronic Hepatitis C In France: Evolution Between 2009 And 2012
- Author
-
Rotily, M., primary, Abergel, A., additional, Branchoux, S., additional, De, Léotoing L., additional, Vainchtock, A., additional, Akremi, R., additional, and Gaudin, A.F., additional
- Published
- 2014
- Full Text
- View/download PDF
3. Mean Annual Cost Of Patients Hospitalized For Chronic Hepatitis C In France: The Hepc-Lone Study
- Author
-
Abergel, A., primary, Rotily, M., additional, Gaudin, A.F., additional, De, Léotoing L., additional, Vainchtock, A., additional, Akremi, R., additional, and Branchoux, S., additional
- Published
- 2014
- Full Text
- View/download PDF
4. PGI12 - Mean Annual Cost Of Patients Hospitalized For Chronic Hepatitis C In France: The Hepc-Lone Study
- Author
-
Abergel, A., Rotily, M., Gaudin, A.F., De, Léotoing L., Vainchtock, A., Akremi, R., and Branchoux, S.
- Published
- 2014
- Full Text
- View/download PDF
5. PGI11 - Burden Of Hospitalizations Related To Chronic Hepatitis C In France: Evolution Between 2009 And 2012
- Author
-
Rotily, M., Abergel, A., Branchoux, S., De, Léotoing L., Vainchtock, A., Akremi, R., and Gaudin, A.F.
- Published
- 2014
- Full Text
- View/download PDF
6. Serum tumor necrosis factor level in chronic hepatitis C
- Author
-
Neuman, M.G., primary, Benhamou, J., additional, Akremi, R., additional, Asselah, T., additional, Martinot, M., additional, Boyer, N., additional, and Marcellin, P., additional
- Published
- 2001
- Full Text
- View/download PDF
7. Genotype 1 is associated with a slower progression of fibrosis in untreqted patients with mild chronic hepatitis C
- Author
-
Marcellin, P., primary, Akremi, R., additional, Cazals, D., additional, Boyer, N., additional, Auperin, A., additional, Vidaud, D., additional, and Degott, C., additional
- Published
- 2001
- Full Text
- View/download PDF
8. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C
- Author
-
Neuman, M. G., Benhamou, J. P., Malkiewicz, I. M., Akremi, R., Shear, N. H., Asselah, T., Ibrahim, A., Boyer, N., Martinot-Peignoux, M., and Jacobson-Brown, P.
- Published
- 2001
- Full Text
- View/download PDF
9. PGI12 Mean Annual Cost Of Patients Hospitalized For Chronic Hepatitis C In France: The Hepc-Lone Study
- Author
-
Abergel, A., Rotily, M., Gaudin, A.F., De, Léotoing L., Vainchtock, A., Akremi, R., and Branchoux, S.
- Full Text
- View/download PDF
10. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.
- Author
-
Hézode C, Lebray P, De Ledinghen V, Zoulim F, Di Martino V, Boyer N, Larrey D, Botta-Fridlund D, Silvain C, Fontaine H, D'Alteroche L, Leroy V, Bourliere M, Hubert-Fouchard I, Guyader D, Rosa I, Nguyen-Khac E, Fedchuk L, Akremi R, Bennai Y, Filipovics A, Zhao Y, and Bronowicki JP
- Subjects
- Adult, Aged, Antiviral Agents adverse effects, Carbamates, Cohort Studies, Drug Therapy, Combination, Female, France, Genotype, Hepatitis C, Chronic complications, Humans, Liver Transplantation adverse effects, Male, Middle Aged, Pyrrolidines, Recurrence, Ribavirin administration & dosage, Sustained Virologic Response, Valine analogs & derivatives, Antiviral Agents administration & dosage, Hepacivirus genetics, Hepatitis C, Chronic drug therapy, Imidazoles administration & dosage, Liver Cirrhosis virology, Sofosbuvir administration & dosage
- Abstract
Background & Aims: Optimally effective treatment for hepatitis C virus genotype 3 (GT3) is urgently needed, particularly in advanced liver disease. Daclatasvir plus sofosbuvir was efficacious in phase 3 studies. Real-world data for daclatasvir+sofosbuvir in advanced GT3 infection are presented from the French Temporary Authorisation for Use programme, which allowed patients in need without other treatment options access to daclatasvir ahead of its market authorization., Methods: Patients with F3/F4 fibrosis and/or extrahepatic hepatitis C virus manifestations, post-liver transplant hepatitis C virus recurrence and/or indication for liver/kidney transplant, were treated with daclatasvir+sofosbuvir (60+400 mg daily) for a recommended duration of 24 weeks. Addition of ribavirin and/or shorter treatment was at physician's discretion. The primary efficacy analysis was sustained virological response at post-treatment week 12 (SVR12; modified intention-to-treat). Safety was assessed by spontaneous adverse event reporting., Results: The efficacy population comprised 333 patients, mostly cirrhotic (77%, of whom 18% were decompensated) and treatment experienced (72%). After 24 weeks of daclatasvir+sofosbuvir, SVR12 was 89% (174/196) overall (95% CI 83.6-92.5%), 98% (43/44) without cirrhosis (95% CI 88.2-99.6%) and 86% (129/150) with any degree of cirrhosis (95% CI 79.5-90.7%), without SVR12 increase in those who received additional ribavirin for 24 weeks (SVR12 82% [50/61; 95% CI 70.5-89.6%]). Among 516 GT3-infected patients with safety data, 5 discontinued for adverse events and 11 died., Conclusions: Daclatasvir+sofosbuvir achieved high SVR12 rates and was well tolerated in this large real-world cohort of GT3-infected patients with advanced liver disease, without benefit of ribavirin in those treated 24 weeks., (© 2017 The Authors Liver International Published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
11. Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.
- Author
-
Lacombe K, Fontaine H, Dhiver C, Metivier S, Rosenthal E, Antonini T, Valantin MA, Miailhes P, Harent S, Batisse D, Pageaux GP, Chas J, Aumaitre H, Dominguez S, Allegre T, Lafeuillade A, Billaud E, De Truchis P, Perre P, Leroy V, De Ledinghen V, Sogni P, Dabis F, Zhao Y, Filipovics A, Fedchuk L, Akremi R, Bennai Y, and Salmon Ceron D
- Subjects
- Adult, Aged, Antiviral Agents adverse effects, Carbamates, Coinfection drug therapy, Drug-Related Side Effects and Adverse Reactions, Female, France, Humans, Imidazoles adverse effects, Male, Middle Aged, Pyrrolidines, Ribavirin adverse effects, Sofosbuvir adverse effects, Sustained Virologic Response, Treatment Outcome, Valine analogs & derivatives, Antiviral Agents administration & dosage, HIV Infections complications, Hepatitis C, Chronic complications, Hepatitis C, Chronic drug therapy, Imidazoles administration & dosage, Ribavirin administration & dosage, Sofosbuvir administration & dosage
- Abstract
Background: Efficacious, well-tolerated, direct antiviral agents have drastically changed the prognosis of hepatitis C virus (HCV) disease, but real-world data for oral treatments are limited in key populations such as HIV/HCV coinfection with advanced liver disease. Daclatasvir (DCV) efficacy and safety was assessed in the French "Autorisation Temporaire d'Utilisation" (ATU) program, providing DCV ahead of market authorization to patients with advanced HCV disease without other treatment options., Methods: This was a subanalysis of HIV/HCV coinfected ATU patients treated with DCV plus sofosbuvir (SOF). Recommended duration was 24 weeks; addition of ribavirin (RBV) and/or shorter treatment was at the physician's discretion. The primary efficacy analysis was sustained virologic response at posttreatment week 12 (SVR12; modified intention-to-treat). Safety was assessed by spontaneous adverse event reporting., Results: The efficacy population (N = 407) was mostly cirrhotic (72%, of whom 18% were decompensated), HCV treatment-experienced (82%), and infected with genotypes 1 (69%), 3 (12%), or 4 (19%). Median CD4 was 555 cells/mm; 95% had HIV RNA <50 copies/mL. Most (74%) were treated for 24 weeks; 14% received RBV. SVR12 was 92% overall (95% confidence interval: 88.6% to 94.0%); 90% (86.4% to 93.2%) in patients with cirrhosis; 95% (88.9% to 97.5%) in patients without cirrhosis. SVR12 was consistent across HCV genotypes and antiretroviral regimens. Among 617 patients with safety data, 7 discontinued for an adverse event and 10 died., Conclusions: DCV+SOF±RBV achieved high SVR12 and was well tolerated in this large real-world cohort of HIV/HCV coinfected patients with advanced liver disease.
- Published
- 2017
- Full Text
- View/download PDF
12. [Regional differences in hospitalisations for complications of chronic hepatitis C in 2012].
- Author
-
Rotily M, Abergel A, Branchoux S, Akremi R, de Léotoing L, Vainchtock A, and Gaudin AF
- Subjects
- Adult, Aged, Feasibility Studies, Female, France epidemiology, Humans, Male, Middle Aged, Prevalence, Retrospective Studies, Young Adult, Health Status Disparities, Hepatitis C, Chronic complications, Hepatitis C, Chronic epidemiology, Hospitalization statistics & numerical data
- Abstract
Objective: Only limited recent information is available concerning the regional incidence and prevalence of chronic hepatitis C (CHC), but this information is critical for optimal definition of public health policies for the management of hepatitis C. The objective of this study was to evaluate the feasibility of mapping potential regional differences in the prevalence of CHC and its complications using data from a health administrative database. Methods: The 2012 PMSI MCO hospital database contains information on diagnosis and healthcare resource use, essentially related to all hospitalisations in France. Hospital stays related to CHC were identified on the basis of ICD-10 disease codes. Hospital stays were classified according to stage of liver disease: non-cirrhotic liver disease, compensated cirrhosis, decompensated cirrhosis or hepatocellular carcinoma (HCC). All study variables were documented for each French administrative region in 2012. Results: In 2012, 12,040 patients were hospitalised in France for a reason related to CHC, corresponding to a standardised age- and gender- adjusted prevalence rate of 19.3/100,000 persons. The highest prevalences of CHC and HCC were observed in the Ile de France, Alsace and Provence-Alpes-Côte-d’Azur regions. Conclusions: This study demonstrates the feasibility of using the PMSI database to identify regional differences in the prevalence of CHC. This information may be useful for planning regional healthcare resource provision for CHC.
- Published
- 2017
13. Chronic hepatitis C: Burden of disease and cost associated with hospitalisations in France in 2012 (The HEPC-LONE study).
- Author
-
Abergel A, Rotily M, Branchoux S, Akremi R, de Léotoing L, Vainchtock A, and Gaudin AF
- Subjects
- Adult, Aged, Carcinoma, Hepatocellular economics, Carcinoma, Hepatocellular epidemiology, Female, France epidemiology, Hospital Mortality, Hospitalization statistics & numerical data, Humans, Liver Cirrhosis economics, Liver Cirrhosis epidemiology, Liver Neoplasms economics, Liver Neoplasms epidemiology, Liver Transplantation economics, Liver Transplantation statistics & numerical data, Male, Middle Aged, Retrospective Studies, Severity of Illness Index, Hepatitis C, Chronic economics, Hepatitis C, Chronic epidemiology, Hospitalization economics
- Abstract
Background and Objective: This retrospective hospital database analysis aimed to determine the burden and cost of hospitalisations related to chronic hepatitis C (CHC) infections in France in 2012., Methods: All hospital stays with CHC (ICD-10 code B18.2) coded as the principal, related or significantly associated diagnosis were extracted from the French National Hospital database 2012 (PMSI). Hospitalisations not directly related to CHC were excluded. Patients were assigned to a liver disease stage, namely non-cirrhotic liver disease, compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma or post-liver transplantation. Costing was performed using French national tariffs and expressed in 2013 Euros. We documented 22,056 hospital stays involving 12,040 patients who were considered to be directly related to CHC. Of these stays, 11,779 (53.4%) were documented in patients with severe complications (decompensated cirrhosis, hepatocellular carcinoma or liver transplantation)., Results and Conclusions: The mean number and duration of hospital stays increased with disease severity. Overall, 1181 patients (9.8%) died during hospitalisation. The total cost of hospital stays for CHC was estimated to be € 61 million, of which 26.4% were attributable to hepatocellular carcinoma, 32.5% to post-liver transplantation and 21.0% to decompensated cirrhosis. Compared with a previous analysis in 2009, the number of patients hospitalised fell by 22%, although the patients hospitalised were overall more severely ill. The total cost of hospitalisation decreased by 8%, with a notably marked reduction in the number of biopsies performed (32%). This study illustrates the persistently high burden of CHC infections in France., (Copyright © 2015 Elsevier Masson SAS. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
14. Role of cytokines in the assessment of the severity of chronic hepatitis C and the prediction of response to therapy.
- Author
-
Neuman MG, Benhamou JP, Ibrahim A, Malkiewicz I, Spircu T, Martinot-Peignoux M, Shear NH, Katz GG, Akremi R, Bourliere M, and Marcellin P
- Subjects
- Enzyme-Linked Immunosorbent Assay, Forecasting, Hepatitis C, Chronic immunology, Humans, Liver Cirrhosis etiology, Liver Cirrhosis prevention & control, Predictive Value of Tests, Severity of Illness Index, Antineoplastic Agents blood, Antiviral Agents therapeutic use, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic pathology, Ribavirin therapeutic use, Tumor Necrosis Factor-alpha analysis
- Abstract
Aims: (i) To characterize serum levels of pro/anti-inflammatory cytokines in non-cirrhotics with hepatitis C; (ii) to correlate levels of these cytokines with degree of disease at baseline; and (iii) to characterize the immuno-modulatory effects of therapy with response., Methods: We studied 103 patients that were part of randomized, controlled, clinical trials. Serum cytokines were measured using enzyme-linked immunosorbent assay., Results: Using standard therapy in the presence and absence of ribavirin, the sustained responders had lower baseline tumor necrosis alpha (TNF-alpha) levels as compared to relapsed responders and non-responders. In patients receiving pegylated therapy, the degree of inflammation as determined by histology was paralleled by high TNF-alpha levels at baseline. In pegylated combination therapy with high dose ribavirin, lower levels of TNF-alpha, transforming growth factor beta (TGF-beta) and fibrosis scores were seen when comparing baseline with follow up. In sustained responders, regardless of therapy, the histological activity scores were lower at follow up as compared to baseline., Conclusions: Pegylated combination therapy reduces and sustains TNF-alpha levels and liver inflammation as shown by the histological activity index. In addition, it is able to reduce fibrosis as judged both by TGF-beta levels and fibrosis scores as compared to standard therapy.
- Published
- 2002
15. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers.
- Author
-
Martinot-Peignoux M, Boyer N, Colombat M, Akremi R, Pham BN, Ollivier S, Castelnau C, Valla D, Degott C, and Marcellin P
- Subjects
- Adult, Female, Follow-Up Studies, Gene Dosage, Humans, Male, Middle Aged, Polymerase Chain Reaction methods, Carrier State blood, Carrier State pathology, DNA, Viral blood, Hepatitis B Surface Antigens analysis, Hepatitis B virus genetics, Liver pathology
- Abstract
Background/aims: A recent NIH research workshop on hepatitis B virus (HBV) revisited the definition of healthy HBsAg carriers. The new definition inactive surface antigen (HBsAg) carriers includes an estimated serum HBV DNA level below 105 copies/ml. However, this cut-off value needs to be confirmed., Methods: Eighty-five consecutive patients, HBsAg-positive/HBeAg-negative with persistently normal alanine aminotransferase (ALT) and undetectable serum HBV DNA with standard assay (Versant HBV DNA Assay (bDNA), Bayer) were prospectively followed for 3.2+/-2.6 (range 0.5-11) years; 58 underwent a liver biopsy. Serum HBV DNA was quantified with a sensitive polymerase chain reaction assay (Cobas Amplicor HBV Monitor, Roche) (sensitivity 200 copies/ml), and liver histology was assessed using the Ishak scoring system., Results: The median serum HBV DNA level was 1300 copies/ml (<200-179 x 10(3) copies/ml), 16% of the subjects had no detectable serum HBV DNA and 98% had levels below 10(5) copies/ml. Histologic lesions were mild (total score <7) in all cases. Loss of HBsAg was observed in three patients, three patients experienced a transient increase in ALT (<2 x upper limit of normal), and serum HBV DNA levels remained stable (1-6 years) in 97% of the 38 patients retested., Conclusions: In our study of inactive HBsAg carriers, the median serum HBV DNA level was 1300 copies/ml, the serum HBV DNA level was below 10(5) copies/ml in 98% of the patients, and remained stable; histological lesions were mild in all cases.
- Published
- 2002
- Full Text
- View/download PDF
16. Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy.
- Author
-
Neuman MG, Benhamou JP, Bourliere M, Ibrahim A, Malkiewicz I, Asselah T, Martinot-Peignoux M, Shear NH, Katz GG, Akremi R, Benali S, Boyer N, Lecomte L, Le Breton V, Le Guludec G, and Marcellin P
- Subjects
- Adult, Alanine Transaminase blood, Drug Therapy, Combination, Female, Follow-Up Studies, Hepacivirus classification, Hepacivirus drug effects, Hepacivirus genetics, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic pathology, Hepatitis C, Chronic virology, Humans, Interferon alpha-2, Liver Cirrhosis blood, Liver Cirrhosis drug therapy, Liver Cirrhosis pathology, Liver Cirrhosis virology, Male, Middle Aged, RNA, Viral blood, Recombinant Proteins, Treatment Outcome, Antiviral Agents therapeutic use, Hepatitis C, Chronic blood, Interferon-alpha therapeutic use, Polyethylene Glycols, Ribavirin therapeutic use, Transforming Growth Factor beta blood, Tumor Necrosis Factor-alpha analysis
- Abstract
Our aims were: (i) to characterize serum levels of tumour necrosis factor alpha (TNF-alpha) and transforming growth factor beta (TGF-beta) in non-cirrhotics with hepatitis C; (ii) to correlate levels of theses cytokines with degree of disease at baseline; (iii) to characterize the immunomodulatory effects of therapy with response and (iv) to compare profiles of cytokines in patients treated with pegylated-interferon alpha-2b monotherapy (PMT) vs its combination with ribavirin (PCT1-low dose ribavirin and PCT2-high dose ribavirin). We studied 56 patients that were part of two randomized, controlled, clinical trials. At baseline, high TNF-alpha levels paralleled the degree of inflammation as determined by histology. In PCT2, a significant reduction was seen in levels of TNF-alpha, TGF-beta and fibrosis scores when comparing baseline with follow-up. In sustained responders, regardless of therapy, the histological activity scores were lower at follow-up as compared to baseline. In conclusion, PCT2 is able to constantly reduce and sustain TNF-alpha levels, which is responsible for the sustained decline in liver inflammation as shown by the histological activity index and it is also able to reduce fibrosis as judged both by TGF-beta levels and fibrosis scores., (Copyright 2002 Elsevier Science Ltd.)
- Published
- 2002
- Full Text
- View/download PDF
17. A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C.
- Author
-
Martinot-Peignoux M, Boyer N, Le Breton V, Le Guludec G, Castelnau C, Akremi R, and Marcellin P
- Subjects
- Enzyme-Linked Immunosorbent Assay, Hepatitis C, Chronic therapy, Humans, RNA, Viral standards, Reagent Kits, Diagnostic, Retrospective Studies, Reverse Transcriptase Polymerase Chain Reaction, Hepacivirus genetics, Hepatitis C, Chronic blood, RNA, Viral blood
- Abstract
The need to improve efficacy of antiviral therapy for chronic hepatitis C has prompted the development of quantitative assays, which allows the assessment of viral load before therapy. The aim of our study was to evaluate the clinical relevance of 3 serum HCV-RNA quantitative assays in 87 patients with chronic hepatitis C, the noncommercially available SuperQuant assay (National Genetic Institute), recently used in large international controlled trials, the most early and widely used Quantiplex HCV RNA v2.0 assay (branched DNA [bDNA] v2.0; Bayer Diagnostics, Puteaux, France), and the new generation Cobas Amplicor HCV Monitor assay (COBAS v2.0; Roche Diagnostics Systems, Meylan, France), which is a semiautomated reverse transcription-polymerase chain reaction (RT-PCR) assay. The level and range of quantification were similar between all assays and a strong correlation was observed over all HCV genotypes among the assays. Recent publications have suggested that the baseline cut-off level of 2 x 10(6) copies/mL, as determined by the SuperQuant assay, is able to discriminate between patients with low viral load from those with high viral load and can be used to predict responses to therapy. Because all 3 assays use different testing technologies we examined how many of our patients fell above this defined cut-off level when tested by the other assays; of 22 patients measured below 2 x 10(6) copies/mL with the SuperQuant assay, 17 of 22 and 19 of 22 patients were eligible with the bDNA v2. 0 and the COBAS v2.0 assays, respectively (P >.05). Our results indicate that the 2 commercial assays can be used to determine treatment schedules in patients with chronic hepatitis C, providing a flexibility in multicenter controlled trials by offering better accessibility of test results.
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.